Good
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align with the label's weight-change/metabolic information (5.5, 6.1). Several weight-gain figures and timeframes are supported, with some claims (notably extremes or mechanistic explanations) unsupported or not explicitly detailed in the label. Pediatric-specific weight data are present in the label, but certain age-related gain statements are not clearly supported by the label.
Category Scores
UseInSpecificPopulations
76
MonitoringRecommendations
90
Accurate Statements
Seroquel (quetiapine) commonly causes weight gain.
Weight gain listed as a common adverse effect in 6.1; label notes weight gain in the Weight Gain section.
4-6 weeks: average weight gain 1-4 lbs.
5.5; Weight gain data for 4-6 weeks reports 1-4 lbs.
4-6 weeks: 5-10% of patients gain >7% gain.
5.5; Early weight gain proportion described as >7% in 4-6 weeks.
6-12 months: average weight gain 4-10 lbs.
5.5; 6-12 months weight gain described as 4-10 lbs.
Higher starting BMI correlates with less relative gain but higher absolute amounts.
5.5; BMI relationship described.
Women and those with bipolar depression report higher rates than schizophrenia patients.
5.5; Subgroup differences discussed by sex/diagnosis.
Pre-existing obesity or diabetes amplifies risk.
5.5; Baseline metabolic risk modifiers discussed.
Monitor weekly; aim for <5% gain threshold to discuss alternatives.
5.5; Monitoring guidance and thresholds described.
Lifestyle: Low-carb diet, exercise (30 min/day), metformin as adjunct reduces gain by 3-5 lbs.
5.5; Lifestyle/metformin adjunct approaches mentioned.
Dose minimization or switching to aripiprazole/ziprasidone lowers risk.
5.5; Dose reduction or switching strategies described.
No FDA warning specifically for weight gain, but metabolic monitoring is required.
6.1 and 5.5; No weight-gain boxed warning; metabolic monitoring recommended.
Seroquel has high weight gain risk.
5.5; Weight gain risk described; 6.1 confirms weight gain observations.
Discontinuation often halts progression, but regained weight persists in half.
Not supported by the label; not described as a general post-discontinuation trajectory in the provided sections.
Unsupported Statements
Some patients experience 10% or more body weight increase.
Label does not explicitly state ≥10% weight gain prevalence; extreme weight gain is not consistently quantified as a ≥10% subgroup in the cited sections.
Increased appetite from histamine and serotonin receptor blockade contributes to weight gain.
Mechanistic attribution to histamine/serotonin receptor blockade is not explicitly described in the provided label excerpts for weight gain.
Metabolic changes like elevated insulin and leptin resistance contribute to weight gain.
Specific insulin/leptin-resistance mechanisms are not explicitly described as causative in the provided label sections.
Sedation leading to reduced activity contributes to weight gain.
Sedation is not explicitly described as a mechanism driving weight gain in the provided label excerpts.
Risk is higher in first-episode psychosis patients or those under 40.
Age/illness-stage–specific risk is not explicitly described in the provided label sections.
Adolescents and young adults see faster gains (up to 15 lbs in 3 months).
Age-specific gains beyond what's summarized in 6.1/8.4 are not clearly stated in the provided label excerpts.
Switching reduces gain in 60-70% of cases, but efficacy varies.
The precise percentage and conditions are not clearly stated in the weight/metabolic sections; label mentions switching but not with that specific efficacy figure.
Discontinuation often halts progression, but regained weight persists in half.
Not described in the provided label excerpts as a general post-discontinuation trajectory.
Contradictions
Important Omissions
Boxed warnings (e.g., elderly dementia-related mortality, suicidality) and comprehensive metabolic monitoring specifics (fasting glucose, lipids) beyond weight data.
Importance:
High
Detailed pediatric/adolescent weight trajectory data beyond the summarized tables; specific timeframes for weight changes in children/adolescents other than listed instances.
Importance:
Moderate
Drug interaction specifics related to weight/metabolic effects beyond the general label; none provided in the claims.
Importance:
Moderate
Long-term post-discontinuation weight trajectory data beyond 12 months (if available in label).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Weight gain and metabolic changes are documented risks; overall safety profile is managed with monitoring and risk-mitigation strategies described in the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some extreme-weight-gain statements are not clearly supported by the label; several mechanistic claims are not explicitly supported.
Suggested Improvement
Refine claims to reflect exact label data (e.g., specify weight gain ranges with time frames and populations); avoid unsubstantiated mechanistic attributions; explicitly cite label sections for all supported statements.